My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 435

    1.

    Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria.

    Song KH, Ko SH, Kim HW, Ahn YB, Lee JM, Son HS, Yoon KH, Cha BY, Lee KW, Son HY.

    Diabetes Care. 2005 Jul;28(7):1718-23.PMID: 15983325 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.

    Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S; HOPE Investigators.

    Am J Kidney Dis. 2003 Nov;42(5):936-42.PMID: 14582037 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.

    Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H.

    Diabetes Care. 2005 Nov;28(11):2728-32.PMID: 16249547 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Serum lipoprotein(a) concentration as a cardiovascular risk factor in Kuwaiti type 2 diabetic patients.

    Abdella NA, Mojiminiyi OA, Akanji AO, Al Mohammadi H, Moussa MA.

    J Diabetes Complications. 2001 Sep-Oct;15(5):270-6.PMID: 11522503 [PubMed - indexed for MEDLINE]Related articles

    5.

    Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study.

    Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo Perin P; Casale Monferrato Study.

    Diabetes Care. 2003 Jul;26(7):2150-5.PMID: 12832328 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

    Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS.

    Control Clin Trials. 1999 Oct;20(5):493-510.PMID: 10503809 [PubMed - indexed for MEDLINE]Related articles

    7.

    Association of reduced red blood cell deformability and diabetic nephropathy.

    Brown CD, Ghali HS, Zhao Z, Thomas LL, Friedman EA.

    Kidney Int. 2005 Jan;67(1):295-300.PMID: 15610255 [PubMed - indexed for MEDLINE]Related articles

    8.

    Evaluation of a simple, random urine test for prospective analysis of proteinuria in Type 2 diabetes: a six year follow-up study.

    Viswanathan V, Chamukuttan S, Kuniyil S, Ambady R.

    Diabetes Res Clin Pract. 2000 Aug;49(2-3):143-7.PMID: 10963826 [PubMed - indexed for MEDLINE]Related articles

    9.

    Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria.

    Turk N, Mornar A, Mrzljak V, Turk Z.

    Diabetes Metab. 2004 Apr;30(2):187-92.PMID: 15223992 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study.

    Araki S, Haneda M, Koya D, Sugimoto T, Isshiki K, Chin-Kanasaki M, Uzu T, Kashiwagi A.

    Diabetologia. 2007 Apr;50(4):867-73. Epub 2007 Jan 16.PMID: 17225121 [PubMed - indexed for MEDLINE]Related articles

    11.

    Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes.

    Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J, Itoshima T, Makino H.

    Diabetes Care. 2005 Dec;28(12):2890-5.PMID: 16306550 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes.

    Jude EB, Anderson SG, Cruickshank JK, Srivatsa A, Tentolouris N, Chandrasekaran R, Gokal R, Boulton AJ.

    QJM. 2002 Jun;95(6):371-7.PMID: 12037245 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Lipoprotein(a) in patients with the nephrotic syndrome: influence of immunosuppression and proteinuria.

    Wanner C, Bartens W, Nauck M, Zäuner I, Greiber S, Schollmeyer P.

    Miner Electrolyte Metab. 1996;22(1-3):26-30.PMID: 8676820 [PubMed - indexed for MEDLINE]Related articles

    14.

    Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes.

    Hiraga T, Kobayashi T, Okubo M, Nakanishi K, Sugimoto T, Ohashi Y, Murase T.

    Diabetes Care. 1995 Feb;18(2):241-4.PMID: 7729305 [PubMed - indexed for MEDLINE]Related articles

    15.

    Renal and retinal microangiopathy after 15 years of follow-up study in a sample of Type 1 diabetes mellitus patients.

    Romero P, Salvat M, Fernández J, Baget M, Martinez I.

    J Diabetes Complications. 2007 Mar-Apr;21(2):93-100.PMID: 17331857 [PubMed - indexed for MEDLINE]Related articles

    16.

    Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.

    Martínez-Ramírez HR, Jalomo-Martínez B, Cortés-Sanabria L, Rojas-Campos E, Barragán G, Alfaro G, Cueto-Manzano AM.

    Am J Kidney Dis. 2006 Jan;47(1):78-87.PMID: 16377388 [PubMed - indexed for MEDLINE]Related articles

    17.

    Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus.

    Cha DR, Kim IS, Kang YS, Han SY, Han KH, Shin C, Ji YH, Kim NH.

    Diabet Med. 2005 Jan;22(1):14-20.PMID: 15606685 [PubMed - indexed for MEDLINE]Related articles

    18.

    Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes.

    Saraheimo M, Forsblom C, Thorn L, Wadén J, Rosengård-Bärlund M, Heikkilä O, Hietala K, Gordin D, Frystyk J, Flyvbjerg A, Groop PH; FinnDiane Study Group.

    Diabetes Care. 2008 Jun;31(6):1165-9. Epub 2008 Mar 17.PMID: 18346990 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Relationship of lipoprotein(a) and its phenotypes with the albumin excretion rate in diabetic patients: a multivariate analysis.

    Hernández C, Chacón P, Martí R, García-Pascual L, Mesa J, Simó R.

    Nephron. 2000 May;85(1):27-33.PMID: 10773752 [PubMed - indexed for MEDLINE]Related articles

    20.

    Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome.

    Wanner C, Rader D, Bartens W, Krämer J, Brewer HB, Schollmeyer P, Wieland H.

    Ann Intern Med. 1993 Aug 15;119(4):263-9.PMID: 8328733 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity